Three types of akinesia in the progressive course of Parkinson's disease.
Narabayashi
H
H
Neurological Clinic, Tokyo, Japan.
D001931:Brain Mapping; D003342:Corpus Striatum / Q000187:drug effects / Q000503:physiopathology; D004298:Dopamine / Q000502:physiology; D015259:Dopamine Agents / Q000627:therapeutic use; D015103:Droxidopa / Q000627:therapeutic use; D005917:Globus Pallidus / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D009069:Movement Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D009434:Neural Pathways / Q000187:drug effects / Q000503:physiopathology; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D013787:Thalamic Nuclei / Q000187:drug effects / Q000503:physiopathology
D015259:Dopamine Agents; D011954:Receptors, Dopamine; D007980:Levodopa; D015103:Droxidopa; D004298:Dopamine